Revolution Medicines Pancreatic Cancer Drug Doubles One-Year Survival in Clinical Trial

Revolution Medicines announced positive Phase III trial results showing its experimental drug daraxonrasib nearly doubled survival in advanced pancreatic cancer patients to 13.2 months versus 6.7 months on chemotherapy when used as second-line therapy. Former Nebraska Senator Ben Sasse, diagnosed with metastatic pancreatic cancer in December with an initial prognosis of three to four months, enrolled in an early-phase trial testing daraxonrasib as first-line therapy and experienced approximately 60% tumor volume reduction. Sasse's CA 19-9 cancer marker dropped from above 8,000 to 374, though he experienced side effects including facial bleeding requiring treatment pauses. The drug, developed at Northwestern University and targeting specific genetic mutations, has generated significant excitement in the pancreatic cancer community, with experts confident of FDA approval even before the Phase III results were published.

Ben Sasse's Pancreatic Cancer Diagnosis and Treatment Journey

• ▪Ben Sasse consulted with MD Anderson and Memorial Sloan Kettering to determine the genetic profile of his tumor
• ▪Ben Sasse's CA 19-9 blood marker level was above 8,000 when he started the trial
• ▪Bob Wolff is a medical oncologist at MD Anderson who treated Ben Sasse
• ▪Ben Sasse received his pancreatic cancer diagnosis in December of the previous year
• ▪Ben Sasse experienced approximately 60% tumor volume reduction while on the trial
• ▪Ben Sasse enrolled in an early phase clinical trial testing Revolution Medicines' daraxonrasib as first line therapy
• ▪Ben Sasse's CA 19-9 blood marker level fell from 579 to 374 in mid-March
• ▪Ben Sasse first experienced symptoms of significant back pain and stomach cramping in October
• ▪Dr. Eileen O'Reilly of Memorial Sloan Kettering advised Ben Sasse to take the opportunity to get into the daraxonrasib trial
• ▪Ben Sasse experienced shooting pain in his back that radiated to his front and caused him to double over during approximately 70% of waking hours
• ▪Shubham Pant is a physician at MD Anderson who was part of Ben Sasse's treatment team
• ▪Ben Sasse was initially given a prognosis of three to four months to live

Revolution Medicines' Daraxonrasib Clinical Trial Results and Impact

• ▪Revolution Medicines published positive topline Phase 3 results for daraxonrasib on Monday
• ▪The RASolute 302 trial showed daraxonrasib alone improved survival of advanced pancreatic cancer patients to 13.2 months versus 6.7 months on chemotherapy for second line therapy
• ▪Pancreatic cancer experts have been confident that approval for daraxonrasib will come even before the Phase 3 results were published

Patient Experience and Side Effects on the Experimental Drug

• ▪Bob Wolff told Ben Sasse that the return of back pain was a good sign the tumor was responding to daraxonrasib

Perspective of Pancreatic cancer medical community

• ▪Dr. Eileen O'Reilly of Memorial Sloan Kettering recommended that Ben Sasse pursue enrollment in the daraxonrasib clinical trial as a treatment opportunity
• ▪The pancreatic cancer medical community has been highly enthusiastic about daraxonrasib since Revolution Medicines released early phase trial data